Oral management of adult patients undergoing hematopoietic stem cell transplantation
Oral management of adult patients undergoing hematopoietic stem cell transplantation
复制标题
DOI：
10.26355/eurrev_201802_14365
复制
发表时间：
2018-02-01
影响因子：
3.3
通讯作者：
Cerroni, L.
中科院分区：
文献类型：
--
作者：
Bollero, P.;Passarelli, P. C.;Cerroni, L.
化疗和造血干细胞移植（HSCT）是目前治疗血液病的主要方法；它们会导致骨髓抑制，并增加患者对严重感染的易感性。口腔是HSCT患者并发症的潜在部位，因为它是可引起全身感染的病原体的入口；这是最常见的副作用的地方之一，从调理治疗派生。牙科化疗前和移植处方的重要性经常被强调，因为这两种疗法都会抑制免疫系统和血小板，使得在这个阶段的每次干预都是高风险的。本文的目的是回顾HSCT的潜在并发症，并从科学文献中推断出可以进行牙科治疗的治疗方法和时间框架，避免患者的重要风险。
Chemotherapy and hematopoietic stem cell transplantation (HSCT) are the current treatments for patients with hematological diseases; they result in myelosuppression, and increase the susceptibility of patients to severe infections. The oral cavity is a potential site of complications in HSCT patients, because it is the entrance for agents that can cause systemic infections; it is one of the most frequent locations for side effects deriving from conditioning therapy. The importance of dental pre-chemotherapy and transplant prescription is often stressed, since both therapies depress the immune system and platelets, making each intervention at this stage a high risk. The aim of this article is to review the potential complications of HSCT, and to extrapolate from the scientific literature the treatments and timeframes in which dental therapies can be performed, avoiding important risks for patients.